Page 1 | Search Results | Hematology, ASH Education Program

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Evidence-Based Minireview: Molecular precision and clinical uncertainty: should molecular profiling be routinely used to guide risk stratification in MDS?

Daniel R. Richardson, Amy E. DeZern

Hematology Am Soc Hematol Educ Program (2021) 2021 (1): 435–438.

https://doi.org/10.1182/hematology.2021000320

Published: 2021

Journal Articles

Lower risk but high risk

Amy E. DeZern

Hematology Am Soc Hematol Educ Program (2021) 2021 (1): 428–434.

https://doi.org/10.1182/hematology.2021000277

Published: 2021

Journal Articles

Treatments targeting MDS genetics: a fool’s errand?

Amy E. DeZern

Hematology Am Soc Hematol Educ Program (2018) 2018 (1): 277–285.

https://doi.org/10.1182/asheducation-2018.1.277

Published: 2018

Journal Articles

Nine years without a new FDA-approved therapy for MDS: how can we break through the impasse?

Amy E. DeZern

Hematology Am Soc Hematol Educ Program (2015) 2015 (1): 308–316.

https://doi.org/10.1182/asheducation-2015.1.308

Published: 2015

Journal Articles

Do somatic mutations in de novo MDS predict for response to treatment?

Mark A. Schroeder, Amy E. DeZern

Hematology Am Soc Hematol Educ Program (2015) 2015 (1): 317–328.

https://doi.org/10.1182/asheducation-2015.1.317

Published: 2015

Journal Articles

Therapy for Aplastic Anemia

Amy E. DeZern, Eva C. Guinan

Hematology Am Soc Hematol Educ Program (2011) 2011 (1): 82–83.

https://doi.org/10.1182/asheducation-2011.1.82

Published: 2011

NARROW

Evidence-Based Minireview: Molecular precision and clinical uncertainty: should molecular profiling be routinely used to guide risk stratification in MDS?

Lower risk but high risk

Treatments targeting MDS genetics: a fool’s errand?

Nine years without a new FDA-approved therapy for MDS: how can we break through the impasse?

Do somatic mutations in de novo MDS predict for response to treatment?

Therapy for Aplastic Anemia

ASH Publications

American Society of Hematology

Evidence-Based Minireview: Molecular precision and clinical uncertainty: should molecular profiling be routinely used to guide risk stratification in MDS?

Lower risk but high risk

Treatments targeting MDS genetics: a fool’s errand?

Nine years without a new FDA-approved therapy for MDS: how can we break through the impasse?

Do somatic mutations in de novo MDS predict for response to treatment?

Therapy for Aplastic Anemia

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only